OncLive’s Post

Watch this on-demand webinar on recent progress in cancer research, including novel treatments, experimental therapies, and drug development. In this session, Aptamer Group CSO, David Bunka discusses how Optimer technology is enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches. https://lnkd.in/ebhQpQXD

Watch the CheckRare interview below with Dr. Brad Elder to learn more about the Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, an investigational #GeneTherapy for people with #FrontotemporalDementia with GRN mutations. 

During Friends of Cancer Research & Parker Institute for Cancer Immunotherapy's Unlocking Complex Cell-based Gene Therapies Session 1 we’ll discuss “Shaping the Future of Cell and Gene Therapies: Challenges & Opportunities.” The session one goals are: • Evaluate opportunities and obstacles of using cell-based gene therapies to treat different types of cancer, including solid tumors. • Explore innovative scientific approaches to enhance the safety and efficacy of cell-based gene therapies. • Discuss methods to overcome challenges in developing new cell-based gene therapies, including scientific and manufacturing limitation and clinical development costs and time. Register here: bit.ly/3VzTYJT Featuring: Toni Ribas, University of California Los Angeles Carl June, University of Pennsylvania Alex Marson, Gladstone Institutes Nicole Verdun, CBER, U.S. FDA Desiree A. H. Walker, Patient Advocate Tom Whitehead, Patient Advocate Iwen Wu, CBER, U.S. FDA

Recognition of the principal gene regulative and gene editing capacities of endogenous estrogens may thoroughly repurpose the genomic and proteomic therapy of cancer

📢 Exciting News in Cancer Treatment😀 !The FDA has approved afamitresgene autoleucel (afami-cel), the first gene therapy for adults with metastatic or unresectable synovial sarcoma. Developed by Adaptimmune, this groundbreaking T cell receptor therapy targets the MAGE-A4 antigen and has shown significant promise in clinical trials. 🔬 FDA Approval Date: August 2024 Clinical Trial Results: 39% overall response rate with a median response duration of 12 months. Significance: First engineered T cell therapy approved for a solid tumor. I assure that this approval brings new hope to patients with advanced synovial sarcoma, offering a potentially life-extending treatment option. I would like to thank for all investigators, study coordinators, CRAs, etc who were involved in all clinicaltrials to commit on getting approval! 🤞 #CancerTreatment #GeneTherapy #FDAApproval #SynovialSarcoma #Adaptimmune #Biotech #CNR #CNRResearch #ClinicalTrials #씨엔알리서치 #임상시험 #유전자치료제 #유럽임상시험 #글로벌CRO https://lnkd.in/gD45dMPM

🔬Dive into the fascinating world of cell and gene therapies: personalized treatments that target cancer and offer long-lasting remissions, with minimal harm to healthy tissues. Learn how innovations and collaboration are fueling a future of successful therapies!🔬

ASGCT President Paula Cannon, PhD, has published an insightful blog post about the recent #FDA approval of #Tecelra (link in first comment), a groundbreaking gene therapy for metastatic synovial sarcoma. This approval marks a significant milestone in the #CGT field, representing the first gene therapy for this rare cancer and the first FDA-approved T cell receptor (#TCR) gene therapy. Dr. Cannon's post highlights the impressive clinical trial results and discusses how this approval underscores the game-changing potential of gene therapy in tackling hard-to-treat cancers. Interested in learning more about CGT for solid tumors and other cutting-edge topics? Be sure to check out our upcoming event (link in the comments below): Advancing Cell Gene Therapy for Cancer, taking place October 16-17 in Philadelphia and virtually. Join #ASGCT to explore the latest advancements, connect with field leaders, and be part of shaping the future of cancer treatment through gene and cell therapies. #ASGCTAdvancing24 #celltherapy #genetherapy #cancerresearch

In this review we talk about cytochrome P450 enzymes and their role in cancer gene therapy. Don't miss the chance to read it!

What are the lessons that we can learn from the unfortunate 7 blood cancer cases in children treated with this and similar therapies? Here are a few: 01) Can we improve this product by directing gene insertion into non-oncogene encoding locations? 02) How do we better identify the viral vector gene insertion locations during the QC process and make that data a part of the batch release criteria? 03) What follow up monitoring gaps can we close to reduce the 14-92 month detection window to decrease the impact on patients and their caregivers? Please add your questions/comments below! #CGT #celltherapy #genetherapy #geneediting https://lnkd.in/gzhfhxYF